AstraZeneca PLC
AZN
$77.41
-$0.55-0.71%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.04B | 6.50B | 6.44B | 6.33B | 5.96B |
| Total Depreciation and Amortization | 4.98B | 4.99B | 4.90B | 4.88B | 4.85B |
| Total Amortization of Deferred Charges | 200.00M | 280.00M | 280.00M | 280.00M | 280.00M |
| Total Other Non-Cash Items | 538.00M | -41.00M | -1.02B | -1.39B | -1.04B |
| Change in Net Operating Assets | -893.00M | -393.00M | 463.00M | -397.00M | 300.00M |
| Cash from Operations | 11.86B | 11.33B | 11.07B | 9.70B | 10.35B |
| Capital Expenditure | -1.92B | -1.74B | -1.64B | -1.53B | -1.36B |
| Sale of Property, Plant, and Equipment | 55.00M | 54.00M | 59.00M | 60.00M | 132.00M |
| Cash Acquisitions | -3.78B | -3.72B | -3.73B | -1.62B | -1.10B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.33B | -2.47B | -2.27B | -2.14B | -1.74B |
| Cash from Investing | -7.98B | -7.88B | -7.58B | -5.23B | -4.06B |
| Total Debt Issued | 6.49B | 7.12B | 7.57B | 6.03B | 3.98B |
| Total Debt Repaid | -5.00B | -5.24B | -4.47B | -3.22B | -5.21B |
| Issuance of Common Stock | 38.00M | 36.00M | 36.00M | 35.00M | 33.00M |
| Repurchase of Common Stock | -81.00M | -81.00M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.63B | -4.64B | -4.47B | -4.48B | -4.49B |
| Other Financing Activities | -840.00M | -807.00M | -877.00M | -877.00M | -876.00M |
| Cash from Financing | -4.00B | -3.62B | -2.21B | -2.51B | -6.57B |
| Foreign Exchange rate Adjustments | -93.00M | -26.00M | -65.00M | -95.00M | -60.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -208.00M | -184.00M | 1.21B | 1.86B | -346.00M |
